turin - SEPTEMBER 9-11, 2021
Neurological and psychiatric disorders have long been perceived as the exclusive consequence of abnormalities in neurons. Increasing knowledge on newly identified functions of non-neuronal cells together with findings of their abnormalities in a variety of brain pathological states and in ageing now suggest a shift from a neurono-centric to a glial-inclusive viewpoint in neuroscience and in neuropsychopharmacology. After the success of the first meeting edition, we would like to continue the discussion of recent preclinical and clinical findings implicating the involvement of non-neuronal cells in initiation, progression or protection of several neuropathologies. Our perspective is that therapeutic strategies aimed at improving/correcting not only neuronal but also non-neuronal cell state and functional performance may open new venues for relevant and undertreated brain diseases.
Focus will be mainly on research in the field of neurodegenerative and neuropsychiatric disorders including AD, PD, ALS, stroke, epilepsy, depression and anxiety, psychosis, chronic pain, multiple sclerosis, rare and orphan diseases, brain tumours and, importantly, on brain aging including AD, PD, ALS, stroke, epilepsy, depression and anxiety, psychosis, chronic pain, multiple sclerosis, rare and orphan diseases, brain tumours and, importantly, on brain aging. Research in the field of diabetes and metabolic disorders for their dramatic influence on brain function will also represent an important part of the meeting. Contributions on any topic ranging from newly identified functions of non-neuronal cells, glia-neuron cross-talk, neural stem cells, blood-brain barrier, neuroglia-vascular interactions, to immune and inflammatory cells and their pharmacological modulation in aging and in diseased brain are welcome.